Trending Industry Today: TIGERMED Leads Gains In Pharmaceutical Outsourcing/contract Research Organization(cro Concept) Stocks
April 26th - The industry of $Pharmaceutical Outsourcing/contract Research Organization(cro Concept)(BK1261.HK)$ is trending higher today with 8 constituents up and TIGERMED leading Gains.$TIGERMED(03
Fangda Holdings (01521.HK)'s revenue for the first quarter was about 63.9 million US dollars, up 8.3% year-on-year
Gelonghui, April 25 | Fangda Holdings (01521.HK) announced that for the three months ended March 31, 2024, the Group recorded a net loss of about 1.0 million US dollars, while the net loss was about 0.9 million US dollars for the same period in 2023; revenue was about 63.9 million US dollars, an increase of 8.3% over the same period of about 59.0 million US dollars in the same period in 2023. After deducting share-based compensation expenses, amortization of intangible assets from mergers and acquisitions, and merger-related expenses, the Group's adjusted net profit was approximately US$2.2 million, an increase of 15.8% over the same period in 2023 of approximately US$1.9 million.
方達控股:2023年度報告
Haitong International: Maintaining Fangda Holdings (01521)'s “superior to market” rating target price reduction of 44% to HK$1.89
The Zhitong Finance App learned that Haitong International released a research report stating that maintaining the “superior to market” rating of Fangda Holdings (01521) was affected by the decline in global biomedical investment and financing growth, adjusted the company's 2024-2026 revenue to US$3,360, and 422 million, respectively; the adjusted net profit was US$0.34, 0.43, and US$52 million, with year-on-year growth rates of 40%, 28%, and 20%, respectively, cutting the target price from HK$3.4 to HK$1.89. In North America, the company acquired Nuro in Toronto, Canada
Fangda Holdings (01521.HK) cancelled 63.1 million shares on April 15
Gelonghui, April 15, 丨 Fangda Holdings (01521.HK) announced that on April 15, 2024, the company cancelled 63.1 million repurchased shares.
[Broker Focus] Sino-Thai International maintains a “neutral” rating of Fangda Holdings (01521) indicating that last year's performance fell short of expectations
Jinwu Financial News | According to the Sino-Thai International Development Research Report, Fangda Holdings (01521)'s revenue in 2023 increased 3.8% year on year to US$260 million, gross profit fell 12.1% year on year to US$78.39 million, and shareholders' net profit fell sharply by 58.0% year on year to US$10.81 million. The bank indicated that performance fell short of expectations. As the 2023 revenue and new orders were worse than expected, the bank lowered the 2024-25E revenue forecast by 15.3% and 18.9% respectively. Since the 2023 shareholders' net profit fell short of expectations, and it will take some time for profit margins to rise according to the current new order situation.
Frontage Holdings' Net Profit Plunges 59% in 2023
Frontage Holdings' (HKG:1521) net profit slumped 58.7% to $10.7 million in 2023 from $25.9 million in the previous year. Basic earnings per share declined to $0.0053 from $0.0126 a year ago, according
Fangda Holdings (01521) announced annual results. After adjustment, net profit of 24 million US dollars decreased by 33.7% year on year
Fangda Holdings (01521) announced the results for the year ended December 31, 2023. The group obtained 2 profits...
FRONTAGE: ANNOUNCEMENT ON ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023
EPNextS Group and Frontage Laboratories, Inc. Announce Collaboration in Early Phase Clinical Trials in the United States to Improve "Drug Lag" and "Drug Loss" Issues in Japan
EXTON, Pa., March 26, 2024 /PRNewswire/ -- EPNextS Group, a Japanese based leading provider of clinical trial solutions, and Frontage Laboratories, Inc., a US based full-service contract research org
Fangda Holdings (01521.HK) plans to hold a board meeting on March 28 to approve the annual results
Gelonghui, March 15, 丨 Fangda Holdings (01521.HK) announced that a board of directors meeting will be held on March 28, 2024 (Thursday) to consider and approve the annual results of the company and its subsidiaries for the year ended 31 December 2023, and to consider the proposed payment of a final dividend (if any).
FRONTAGE: DATE OF BOARD MEETING
Trending Industry Today: WUXI BIO Leads Losses In Pharmaceutical Outsourcing/contract Research Organization(cro Concept) Stocks
March 14th - The industry of $Pharmaceutical Outsourcing/contract Research Organization(cro Concept)(BK1261.HK)$ is trending lower today with 3 constituents up, 5 constituents down and WUXI BIO leadin
Changes in Hong Kong stocks | Fangda Holdings (01521) rose more than 8%, leading the CRO concept drug, Kangde, once again announced a major buyback of local pharmaceutical companies or additional innovative drugs
CRO concept stocks picked up collectively. As of press release, Fangstar Holdings (01521) rose 7.89% to HK$1.64; Kingsley Biotech (01548) rose 7.65% to HK$15.48; Kanglong Chemical (03759) rose 5.26% to HK$10.2; and Pharmaceuticals Kangde (02359) rose 3.74% to HK$48.55.
Despite Hitting HK$1.67, Frontage Holdings Insiders Still Sold Too Soon
Frontage Holdings Corporation's (HKG:1521) stock price has dropped 11% in the previous week, but insiders who sold US$746k in stock over the past year have had less luck. The average selling price of
Fangda Holdings (01521.HK) spent HK$1.465,800 to buy back 838,000 shares on February 27
On February 27, Gelonghui Holdings (01521.HK) announced that on February 27, it spent HK$1.465,800 to repurchase 838,000 shares at a price of HK$1.76-1.74 per share.
Fangda Holdings (01521) spent about HK$2,640,900 to buy back 1.464 million shares on February 26
According to the Zhitong Finance App, Fangda Holdings (01521) announced that on February 26, 2024, it spent about HK$2.64,000 to buy back 1.464 million shares.
On February 22, Fangda Holdings spent about HK$5.2715 million to repurchase 2,848 million shares
Fangda Holdings (01521) announced that on February 22, 2024, it spent approximately HK$5.2715 million to repurchase 2,848 million shares.
Fangda Holdings (01521) spent about HK$5.2715 million to repurchase 2,848 million shares on February 22
Fangda Holdings (01521) announced that on February 22, 2024, it cost approximately HK$5.2715 million to repurchase 284...
Fangda Holdings (01521) spent HK$6.9471 million to buy back 3.802 million shares on February 21
Fangda Holdings (01521) issued an announcement to spend HK$6.9471 million to repurchase 3 on February 21, 2024...
No Data